CIRM Funded Clinical Trials

A phase I/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19


Disease Area:
Investigator:
Institution:
CIRM Grant:
Award Value:
$315,000.00
Trial Sponsor:
Celularity Inc.
Trial Stage:
Phase 1/2
Trial Status:
Active, not recruiting
Targeted Enrollment:
86
ClinicalTrials.gov ID:

Details:

This trial will use blood stem cells obtained from the placenta to generate natural killer (NK) cells, a type of white blood cell that is a vital part of the immune system, and administer them to patients with COVID-19.  NK cells play an important role in defense against cancer and in fighting off viral infections.  The goal is to administer these cells to locate the active sites of COVID-19 infection and destroy the virus-infected cells. 

Design:

Phase I/II Study

Goal:

Safety, tolerability, and efficacy 

CIRM Clinical Trial Resources


Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox


Video on Stem Cell Trials


Other Resources

ISSCR Patient Website

ClinicalTrials.gov